Exparel Use in Bilateral TAP Blocks for Postoperative Pain Control

Completed · Phase 4

Conditions studied: Postoperative Pain, Surgery, Anesthesia, Local

In brief

To determine if Exparel (Liposomal Bupivacaine, an FDA approved drug) use in ultrasound guided Transversus Abdominis Plane (TAP) blocks may reduce opioid requirement use postoperatively, reduce pain scores postoperatively, reduce incidence of nausea in the postop period, and decrease length of hospital stay

Key facts

Study ID

NCT03878888

Run by

St. Luke's Hospital, Pennsylvania

People needed

52

Starts

2019-01-15

Expected to finish

2019-07-01

Last updated by the study team

2020-12-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Women of Reproductive Potential
• Men of Reproductive Potential
• Minorities
• Healthy Controls/Volunteers
• Employees/Students
• Vulnerable populations (trauma victims, students > 18 yrs age, aged infirm, substance abusers, impoverished, terminally ill,)
• patients of above inclusion criteria who 1) are not candidates of an neuraxial blockade (i.e. epidural) for postoperative pain control 2) who underwent a laparoscopic to open procedure intraoperatively

You may not qualify if…

• advanced dementia, not oriented to time or place
• advanced liver disease
• pregnant patients
• allergy to amide local anesthesia
• allergy to methemoglobinemia

Where it is running

• St. Luke's University Hospital Health Network — Bethlehem, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.